An improved understanding of the biological processes that drive neuromyelitis optica spectrum disorder (NMOSD) has led to treatment advancements in recent years. In a presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, Sean Pittock, MD, director of the Mayo Clinic’s Center for…
Uplizna
Horizon Therapeutics is growing its rare disease portfolio by acquiring the biotechnology company Viela Bio, including the approved medicine Uplizna for treating neuromyelitis optica spectrum disorder (NMOSD). “This acquisition represents a significant step forward in advancing our strategy — to expand our pipeline,” Tim Walbert, chairman,…
Recent Posts
- Estrogen may drive brain inflammation in NMOSD: Mouse study
- I may have the dragon fruit of diseases, but let’s not compare apples to oranges
- 17-year-old advocate shares her NMOSD story to raise awareness
- Brain, nerve damage link to relapse, disability in AQP4-related NMOSD
- With NMOSD, my to-do lists now include staying well, as well as staying busy